Free Trial

Legend Biotech (NASDAQ:LEGN) Reaches New 12-Month Low Following Analyst Downgrade

Legend Biotech logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Legend Biotech hit a new 52-week low after Evercore downgraded the stock from outperform to in-line; shares fell from a prior close of $17.50 to a low of $16.09.
  • Analyst sentiment remains a “Moderate Buy,” with nine Buy, six Hold, and one Sell rating and an average price target of $50.85.
  • Latest quarterly EPS of $0.14 beat the $0.01 consensus estimate, while revenue of $359.5 million slightly missed forecasts but rose 32% year over year.
  • Five stocks we like better than Legend Biotech.

Shares of Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Get Free Report) reached a new 52-week low during trading on Monday after Evercore downgraded the stock from an outperform rating to an in-line rating. The stock traded as low as $16.09 and last traded at $15.9850, with a volume of 2,082,893 shares changing hands. The stock had previously closed at $17.50.

A number of other research firms have also weighed in on LEGN. Weiss Ratings raised Legend Biotech from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, November 9th. HC Wainwright reaffirmed a "buy" rating on shares of Legend Biotech in a research note on Friday, October 30th. Raymond James Financial reiterated an "outperform" rating and set a $58.00 price target on shares of Legend Biotech in a report on Monday, July 27th. Morgan Stanley lowered their price target on shares of Legend Biotech from $49.00 to $43.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 11th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Legend Biotech from $35.00 to $33.00 and set a "neutral" rating for the company in a report on Friday, October 9th. Nine research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Legend Biotech has an average rating of "Moderate Buy" and an average price target of $50.85.

Check Out Our Latest Stock Analysis on LEGN

Insider Transactions at Legend Biotech

In related news, CFO Carlos Santos sold 5,430 shares of the firm's stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $9.14, for a total transaction of $49,630.20. Following the completion of the sale, the chief financial officer directly owned 14,246 shares of the company's stock, valued at approximately $130,208.44. This trade represents a 27.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Corazon (Corsee) D. Sanders sold 27,370 shares of the business's stock in a transaction dated Tuesday, September 29th. The shares were sold at an average price of $9.46, for a total transaction of $258,920.20. Following the completion of the sale, the director owned 52,731 shares in the company, valued at approximately $498,835.26. This trade represents a 34.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.02% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Legend Biotech

Several institutional investors and hedge funds have recently modified their holdings of LEGN. Assenagon Asset Management S.A. purchased a new position in Legend Biotech during the 2nd quarter valued at about $55,307,000. Squarepoint Ops LLC boosted its stake in shares of Legend Biotech by 60.4% in the second quarter. Squarepoint Ops LLC now owns 769,252 shares of the company's stock valued at $22,216,000 after purchasing an additional 289,772 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Legend Biotech by 29.5% in the first quarter. Renaissance Technologies LLC now owns 521,800 shares of the company's stock valued at $9,439,000 after purchasing an additional 119,000 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of Legend Biotech by 343.6% in the first quarter. Arrowstreet Capital Limited Partnership now owns 406,901 shares of the company's stock valued at $7,361,000 after purchasing an additional 315,176 shares in the last quarter. Finally, Tidal Investments LLC grew its holdings in shares of Legend Biotech by 34.0% in the second quarter. Tidal Investments LLC now owns 240,476 shares of the company's stock valued at $6,945,000 after purchasing an additional 61,023 shares in the last quarter. Hedge funds and other institutional investors own 70.89% of the company's stock.

Legend Biotech Stock Performance

The firm's 50 day moving average is $19.57 and its two-hundred day moving average is $22.12. The stock has a market capitalization of $3.10 billion, a PE ratio of -1,597.40 and a beta of 0.55.

Legend Biotech (NASDAQ:LEGN - Get Free Report) last posted its quarterly earnings results on Tuesday, November 10th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.01 by $0.13. The company had revenue of $359.50 million during the quarter, compared to analysts' expectations of $361.46 million. Legend Biotech had a negative net margin of 0.02% and a negative return on equity of 0.03%. The firm's revenue was up 32.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.05) EPS. On average, analysts anticipate that Legend Biotech Corporation Sponsored ADR will post -0.02 EPS for the current year.

Legend Biotech Company Profile

(Get Free Report)

Legend Biotech is a biotechnology company focused on developing cell therapies for cancer, with an emphasis on chimeric antigen receptor (CAR) T-cell treatments. Founded in 2014, the company is headquartered in Somerset, New Jersey, and conducts research and development activities in the United States and China. Its lead product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend developed the therapy with Janssen, now part of Johnson & Johnson's Innovative Medicine business, which collaborates on its commercialization.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Legend Biotech Right Now?

Before you consider Legend Biotech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Legend Biotech wasn't on the list.

While Legend Biotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines